Effect of Intravenous High-Dose Selenium Supplementation in Patients with Systemic Inflammatory Response Syndrome: A Pilot Study.
- Author:
Mi Jeoung KIM
1
;
Ki Jong LEE
;
In Myung OH
;
Dong Hyun OH
;
Kyoung Hwa YOO
;
Ju Sang PARK
;
Eun Jeong JANG
;
Sang Jong PARK
;
Sang Woon PARK
;
Sang Jung KIM
;
Hyun Wook BAIK
Author Information
1. Department of Internal Medicine, Bundang Jesaeng Hospital, Seongnam, Korea. hbaik@dmc.or.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Selenium;
Systemic inflammatory response syndrome;
Prognosis;
APACHE II
- MeSH:
Acute-Phase Proteins;
APACHE;
C-Reactive Protein;
Humans;
Leukocytes;
Oxidative Stress;
Pilot Projects;
Prognosis;
Selenium;
Severity of Illness Index;
Systemic Inflammatory Response Syndrome
- From:Korean Journal of Medicine
2013;84(4):531-540
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Systemic inflammatory response syndrome (SIRS) can induce occurrence of oxidative stress. Several reports have evaluated selenium supplementation in SIRS patients with encouraging results. Therefore, we evaluated the effect of intravenous high-dose selenium supplementation in patients with SIRS. METHODS: Patients were randomly assigned to one of two groups: the selenium group (800 microg/day of selenoic acid by intravenous bolus injection for 7 days) or the placebo group. Physical and biochemical measurements were used to assay acute phase reactants, severity of illness index and serum selenium concentration. RESULTS: A total of 23 patients classified as mild-to-moderate severity of illness index were enrolled between March 2010 and October 2011. Serum selenium concentration increased in the selenium group after intervention, but there was no significant change in the placebo group. In the selenium group, the white blood cell (WBC) count, serum level of c-reactive protein (CRP), Acute Physiology and Chronic Health Evaluation II (APACHEII) score and Sequential Organ Failure Assessment (SOFA) score improved significantly by days 7 and 14 compared with day 0. In the placebo group, only the serum CRP level at day 14 and APACHE II score at days 7 and 14 improved significantly compared to day 0. CONCLUSIONS: Intravenous supplementation with high-dose selenium improved acute phase reactants and the severity of illness index in patients with SIRS. However, larger prospective clinical trials are required to determine the efficacy of selenium supplementation in SIRS patients.
